Rabeprazole Impedes the Development of Reflux-Induced  Esophageal Cancer in a Surgical Rat Model

Rabeprazole Impedes the Development of Reflux-Induced Esophageal Cancer in a Surgical Rat Model

  • نوع فایل : کتاب
  • زبان : انگلیسی
  • مؤلف : Tomoharu Miyashita Furhawn A. Shah Guy P. Marti Jiaai Wang Pramod Bonde Michael K. Gibson Tetsuo Ohta Elizabeth A. Montgomery Mark D
  • چاپ و سال / کشور: 2010

Description

Background The role of proton pump inhibitors in Barrett’s metaplasia and esophageal adenocarcinoma has been an area of controversy. Aims We evaluated the effectiveness of the proton pump inhibitor rabeprazole as a chemoprevention agent in a surgical rat reflux model of esophageal cancer. Methods The rat reflux model was created by performing a jejuno-esophagostomy on Sprague–Dawley rats. The surgery promoted the reflux of gastro-duodenal contents into the esophagus. Rabeprazole sodium (Eisai, Tokyo, Japan) was dissolved in 0.9% physiological saline to a desired concentration of 1.5% (W/V). Beginning 4 weeks post-surgery, all animals were administered either 0.2 ml per 100 g body weight injections of rabeprazole or equivalent injections of saline 3 days per week into the subcutaneous tissue of the back. Forty animals were killed 40 weeks after surgery and their esophagi were examined. Of these, 23 were included in the control group, while the remaining 17 were subjected to rabeprazole. Results While 74% (17/23) of the controls developed esophageal cancer, animals administered rabeprazole had an incidence of cancer of 29% (5/17) (p\0.05, Fisher’s exact test). Barrett’s metaplasia was found on 100% (23/23) of the rats in the placebo group, but there was a protective effect in the rabeprazole group with 65% (11/17) of the rats displaying signs of Barrett’s metaplasia (p\0.05, Fisher’s exact test). All of the rats developed proliferative hyperplasia. Conclusions Rabeprazole protected against the development of esophageal cancer in a clinically relevant surgical reflux model. Rabeprazole warrants further investigation for potential clinical use as a chemoprevention agent.
Dig Dis Sci (2011) 56:1309–1314 DOI 10.1007/s10620-010-1465-1 Received: 19 July 2010 / Accepted: 12 October 2010 / Published online: 30 October 2010
اگر شما نسبت به این اثر یا عنوان محق هستید، لطفا از طریق "بخش تماس با ما" با ما تماس بگیرید و برای اطلاعات بیشتر، صفحه قوانین و مقررات را مطالعه نمایید.

دیدگاه کاربران


لطفا در این قسمت فقط نظر شخصی در مورد این عنوان را وارد نمایید و در صورتیکه مشکلی با دانلود یا استفاده از این فایل دارید در صفحه کاربری تیکت ثبت کنید.

بارگزاری